alendronate has been researched along with Cystic Fibrosis of Pancreas in 6 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo." | 6.73 | Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). ( Adachi, JD; Berthiaume, Y; Freitag, A; Ioannidis, G; Jeanneret, A; Kennedy, CC; Matouk, E; Nixon, M; O'Neill, J; Papaioannou, A; Paterson, N; Pui, M; Rabin, HR; Villeneuve, J; Webber, C, 2008) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 6.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| "Osteoporosis is a disorder of bone mineralisation occurring in about one third of adults with cystic fibrosis." | 3.01 | Bisphosphonates for osteoporosis in people with cystic fibrosis. ( Chang, AB; Conwell, LS; Jeffery, TC, 2023) |
| "Alendronate therapy was well tolerated and produced a significantly greater increase in BMD over 12 months compared with placebo." | 2.73 | Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial). ( Adachi, JD; Berthiaume, Y; Freitag, A; Ioannidis, G; Jeanneret, A; Kennedy, CC; Matouk, E; Nixon, M; O'Neill, J; Papaioannou, A; Paterson, N; Pui, M; Rabin, HR; Villeneuve, J; Webber, C, 2008) |
| "The alendronate-treated patients gained (mean +/- SD) 4." | 2.71 | Efficacy of alendronate in adults with cystic fibrosis with low bone density. ( Aris, RM; Blackwood, AD; Brown, SA; Caminiti, M; Chalermskulrat, W; Guillen, U; Hecker, TM; Hensler, M; Lark, RK; Lester, GE; Neuringer, IP; Ontjes, DA; Renner, JB, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 2 (33.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Jeffery, TC | 1 |
| Chang, AB | 1 |
| Conwell, LS | 1 |
| Le Henaff, C | 1 |
| Velard, F | 1 |
| Jacquot, J | 1 |
| Bianchi, ML | 1 |
| Colombo, C | 1 |
| Assael, BM | 1 |
| Dubini, A | 1 |
| Lombardo, M | 1 |
| Quattrucci, S | 1 |
| Bella, S | 1 |
| Collura, M | 1 |
| Messore, B | 1 |
| Raia, V | 1 |
| Poli, F | 1 |
| Bini, R | 1 |
| Albanese, CV | 1 |
| De Rose, V | 1 |
| Costantini, D | 1 |
| Romano, G | 1 |
| Pustorino, E | 1 |
| Magazzù, G | 1 |
| Bertasi, S | 1 |
| Lucidi, V | 1 |
| Traverso, G | 1 |
| Coruzzo, A | 1 |
| Grzejdziak, AD | 1 |
| Papaioannou, A | 1 |
| Kennedy, CC | 1 |
| Freitag, A | 1 |
| Ioannidis, G | 1 |
| O'Neill, J | 1 |
| Webber, C | 1 |
| Pui, M | 1 |
| Berthiaume, Y | 1 |
| Rabin, HR | 1 |
| Paterson, N | 1 |
| Jeanneret, A | 1 |
| Matouk, E | 1 |
| Villeneuve, J | 1 |
| Nixon, M | 1 |
| Adachi, JD | 1 |
| Aris, RM | 1 |
| Lester, GE | 1 |
| Caminiti, M | 1 |
| Blackwood, AD | 1 |
| Hensler, M | 1 |
| Lark, RK | 1 |
| Hecker, TM | 1 |
| Renner, JB | 1 |
| Guillen, U | 1 |
| Brown, SA | 1 |
| Neuringer, IP | 1 |
| Chalermskulrat, W | 1 |
| Ontjes, DA | 1 |
| Girón, RM | 1 |
| Sánchez Moliní, P | 1 |
| García Vadillo, A | 1 |
| Quintana, ML | 1 |
| Rodríguez Salvanés, F | 1 |
| Jiménez, I | 1 |
| Mancha, A | 1 |
| Cisneros, C | 1 |
| Ancochea, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Osteoporosis in Cystic Fibrosis: Study of Bone Mass and Bone Metabolism, and Prospective Randomized Therapeutic Trial.[NCT01812551] | Phase 3 | 171 participants (Actual) | Interventional | 2002-10-31 | Completed | ||
| A Multicentre, Double-Blind, Randomized Placebo-Controlled Study of 70mg Alendronate Once Weekly for the Prevention and Treatment of Osteoporosis in Canadian Adult Cystic Fibrosis Patients[NCT00157690] | Phase 4 | 56 participants (Actual) | Interventional | 2003-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for alendronate and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Bisphosphonates for osteoporosis in people with cystic fibrosis.
Topics: Adult; Alendronate; Bone Density Conservation Agents; Child; Cystic Fibrosis; Diphosphonates; Female | 2023 |
3 trials available for alendronate and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Treatment of low bone density in young people with cystic fibrosis: a multicentre, prospective, open-label observational study of calcium and calcifediol followed by a randomised placebo-controlled trial of alendronate.
Topics: Absorptiometry, Photon; Adolescent; Alendronate; Biomarkers; Bone Density; Bone Density Conservation | 2013 |
Alendronate once weekly for the prevention and treatment of bone loss in Canadian adult cystic fibrosis patients (CFOS trial).
Topics: Administration, Oral; Adult; Alendronate; Bone Density; Bone Density Conservation Agents; Canada; Co | 2008 |
Efficacy of alendronate in adults with cystic fibrosis with low bone density.
Topics: Administration, Oral; Adult; Alendronate; Analysis of Variance; Bone Density; Bone Resorption; Cysti | 2004 |
2 other studies available for alendronate and Cystic Fibrosis of Pancreas
| Article | Year |
|---|---|
Bone health in cystic fibrosis: use of oral bisphosphonates.
Topics: Alendronate; Bone Density; Bone Density Conservation Agents; Calcifediol; Calcium; Cystic Fibrosis; | 2013 |
[Protocol for prevention and treatment of osteoporosis in patients with cystic fibrosis].
Topics: Adult; Alendronate; Bone Density; Calcium Compounds; Clinical Protocols; Cystic Fibrosis; Dietary Su | 2005 |